Ablynx today announced the appointment of Markus L.E. Ewert, PhD, MBA, as Chief Business Officer (CBO).
Effective from 20 June 2017, Dr Ewert will lead the Company’s business development and corporate strategy activities and become a member of the Executive Committee. Dr Ewert has worked for nearly 30 years in the life sciences industry and has held a number of senior business and commercial positions.
Until recently, Dr Ewert headed the Business Development team of the Healthcare division of General Electric and in that capacity executed numerous deals. Prior to that, he worked at Novartis in its Cardiovascular and Metabolism franchise and later moved to the Molecular Diagnostics unit as Head of Strategy, Global BD&L, and M&A. Before joining Novartis, Dr Ewert was CEO of two biotech companies and had been at The Boston Consulting Group serving as an advisor to pharmaceutical and chemical companies.
Dr Ewert holds a PhD in molecular biology from the University of Heidelberg and an MBA from the University of Chicago.
Welcoming Dr Ewert to the team, Dr Edwin Moses, CEO of Ablynx, said: “Markus brings extensive experience in leading business development teams and executing licensing deals and acquisitions. Having held senior positions in big pharma as well as in biotech and consultancy firms, he is ideally suited to become part of our Executive Committee and play an important role in helping Ablynx achieve its business objectives.”
Commenting on his appointment, Dr Ewert added: “I am very excited to join the Ablynx team and lead their business development and strategy activities. Ablynx’s Nanobody® platform has been clearly demonstrated to be a very powerful tool in the development of potentially new and important therapeutics. I am looking forward to strengthening the company’s existing relationships with pharmaceutical companies, creating new partnering and strategic opportunities to further build the product pipeline, and advancing the company.”
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).